Zymeworks Announces Participation in Upcoming Investor Conference
Zymeworks Provides Corporate Update And Reports Third Quarter 2023 Financial Results
Zymeworks Presents Preclinical Data on Trispecific T Cell Engager Therapeutic Programs at the Society for Immunotherapy of Cancer (SITC) Conference
We are pleased to present preclinical data associated with our Trispecific T Cell Engager (TriTCE) therapeutic programs in two poster presentations at the annual SITC Conference, taking place November 1-4 in San Diego, CA. The poster presentation titled “TriTCE Co-Stim: A novel trispecific T cell engager platform, with integrated CD28 costimulation, engineered to widen the […]
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Showcases Updated Clinical Data for Zanidatamab at the 2023 ESMO Annual Congress
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals and BeiGene, updated data from two ongoing clinical trials evaluating zanidatamab, a HER2-targeted bispecific antibody for the treatment of solid tumors, at the European Society of Medical Oncology (ESMO) Annual Congress taking place October 20-24 in Madrid, Spain. Poster Presentation Information: Title: Zanidatamab (zani) […]
Zymeworks To Host Third Quarter 2023 Results Conference Call
Zymeworks to Present on Clinical and Preclinical Programs at Multiple Upcoming Medical Conferences
Zymeworks is pleased to announce new and updated clinical and preclinical data presentations at the following medical conferences. 14th Annual World Bispecific Summit October 2-4, 2023 Boston, MA Dr. Nina Weisser, Director, Multispecific Antibody Therapeutics at Zymeworks will lead a seminar on Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid […]
Zymeworks To Host Second Quarter 2023 Results Conference Call
Zymeworks Announces Participation in Upcoming Investor Conference
Zymeworks Appoints New Director
Zymeworks Set To Join Russell 3000®, Russell 2000®, And Russell Microcap® Indexes
Jazz Pharmaceuticals and Zymeworks Present Positive Pivotal Phase 2b Trial Data at ASCO 2023 Evaluating Zanidatamab in HER2-Amplified Biliary Tract Cancers
